Treats hypertension. ANDA 210028, held by Zydus Pharmaceuticals (USA). Atenolol; Chlorthalidone.
As of Nov 22, 2026, ANDA 210028 (Atenolol and Chlorthalidone), held by Zydus Pharmaceuticals (USA), was first approved by FDA on Mar 8, 2019, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 8, 2019 | Original application | Approved | None posted |
| Atenolol and Chlorthalidone50MG;25MG · tablet;oral | Atenolol; Chlorthalidone | Rx |
| Atenolol and Chlorthalidone100MG;25MG · tablet;oral | Atenolol; Chlorthalidone | Rx |
| Mar 1, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 8, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters